Dose-ranging, PK, Safety, Efficacy Study of Osanetant in Patients With Moderate/Severe VMS Associated With Menopause

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 30, 2022

Primary Completion Date

March 4, 2023

Study Completion Date

March 4, 2023

Conditions

Post-menopausal Vasomotor Symptoms

Interventions

DRUG

ACER-801 50 mg BID

50 mg BID (twice daily)

DRUG

ACER-801 100 mg BID

100 mg BID (twice daily)

DRUG

ACER-801 200 mg BID

200 mg BID (twice daily)

DRUG

Placebo

Trial Locations (1)

Spaulding Clinical Research, West Bend